Related videos:
Sources:
1. Medicines T. Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial. Accessed June 4, 2023.
2. Technoderma Medicines Doses TDM-105795 in Phase 1b (MAD) Androgenetic Alopecia Multi-Dose Escalation Clinical Trial. Accessed June 4, 2023.
3. TechnoDerma Medicines Inc. Accessed June 6, 2023.
4. Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial. BioSpace. Accessed June 4, 2023.
5. US Patent for Small molecule compound and synthesizing method and uses thereof Patent (Patent # 9,920,022 issued March 20, 2018) – Justia Patents Search. Accessed June 4, 2023.
6. Li JJ, Mitchell LH, Dow RL. Thyroid receptor agonists for the treatment of androgenetic alopecia. Bioorg Med Chem Lett. 2010;20(1):306-308. doi:10.1016/j.bmcl.2009.10.109
7. Contreras-Jurado C, García-Serrano L, Martínez-Fernández M, Ruiz-Llorente L, Paramio JM, Aranda A. Impaired Hair Growth and Wound Healing in Mice Lacking Thyroid Hormone Receptors. Plateroti M, ed. PLoS ONE. 2014;9(9):e108137. doi:10.1371/journal.pone.0108137
8. Technoderma Medicines Inc. A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Dose TDM-105795 Topical Solution in Healthy Male Subjects With AGA. clinicaltrials.gov; 2022. Accessed June 2, 2023.
9. Technoderma Medicines Inc. A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects With Androgenetic Alopecia. clinicaltrials.gov; 2023. Accessed June 2, 2023.
source
